Palliative Rx for prostate ca wins OK from FDA
Trelstar (22.5 mg triptorelin pamoate) has received FDA marketing approval as a twice-yearly intramuscular gonadotropin-releasing hormone (GnRH) agonist.
Trelstar (22.5 mg triptorelin pamoate) has received FDA marketing approval as a twice-yearly intramuscular gonadotropin-releasing hormone (GnRH) agonist. Trelstar suppresses testosterone production for six months, according to manufacturer Watson Pharmaceuticals. Approval was based on a 12-month, phase III efficacy and safety study of Trelstar given every six months in patients with advanced disease. Trelstar produced a mean testosterone serum level of 12.8 ng/dL from month two through month 12, which was well below castration levels associated with androgen deprivation therapy, according to Watson.
By day 29, 97.5% of the clinical trial patients achieved castrate level, and more than 98% of all patients were below castrate level at month six and month 12. Median prostate-specific antigen (PSA) was also reduced by 96.4% at the end of the study. The most commonly reported adverse event was hot flushes (71.7%).
Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology
September 20th 2022Authors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.
Data Support Early Genetic Testing in HRR+ mCRPC Managed With Olaparib
January 27th 2024Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.
